Olaparib: Phase III started

AstraZeneca disclosed in its 2Q14 financial results that it began the double-blind, placebo-controlled, international Phase III OlympiA trial to evaluate 100 and 150 mg oral olaparib twice daily for up to a year in about 7,600 patients. OlympiA is enrolling patients with high-risk HER2-negative primary breast cancer who have germline breast cancer early onset (BRCA) mutations and have completed local treatment and neoadjuvant or adjuvant chemotherapy. AZ expects to submit regulatory applications for olaparib to treat breast cancer in the U.S. and EU in 2016. ...